[go: up one dir, main page]

PE20081161A1 - COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS - Google Patents

COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Info

Publication number
PE20081161A1
PE20081161A1 PE2007001544A PE2007001544A PE20081161A1 PE 20081161 A1 PE20081161 A1 PE 20081161A1 PE 2007001544 A PE2007001544 A PE 2007001544A PE 2007001544 A PE2007001544 A PE 2007001544A PE 20081161 A1 PE20081161 A1 PE 20081161A1
Authority
PE
Peru
Prior art keywords
tetrahydrocyclopenta
cyane
indol
androgen receptor
receptor modulators
Prior art date
Application number
PE2007001544A
Other languages
English (en)
Inventor
Konstantinos Gavardinas
Jonathan Edward Green
Donald Paul Matthews
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20081161A1 publication Critical patent/PE20081161A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DERIVADO DE TETRAHIDROCICLOPENTA [b]INDOL, DE FORMULA I, DONDE * EN EL CARBONO C REPRESENTA LAS CONFIGURACIONES R, S O R/S; R1 ES CIANO, -CH=NOCH3, -OCHF2, -OCF3; R2 ES -COR2a, -SO2R2b; R2a ES ALQUILO C1-C4, ALCOXI C1-C4, CICLOPROPILO, ENTRE OTROS; R2b ES ALQUILO C1-C4, CICLOPROPILO O -NH2, ENTRE OTROS; R3 ES PIRIDINILO, PIRAZINILO, TIAZOLILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER DE ISOPROPILO DEL ACIDO (S)-(7-CIANO-4-PIRIDIN-2-ILMETIL-1,2,3,4-TETRAHIDRO-CICLOPENTA[b]INDOL-2-IL)-CARBAMICO; (R)-N'-[4-(4-AMINO-TIAZOL-5-ILMETIL)-7-CIANO-1,2,3,4-TETRAHIDRO-CICLOPENTA[b]INDOL-2-IL)-N,N-DIMETILSULFAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES AGONISTA DE ANDROGENO DE LA PROSTATA O VESICULA SEMINAL UTIL EL TRATAMIENTO DE HIPOGONADISMO, REDUCCION DE MASA OSEA, SARCOPENIA, DISFUNCION SEXUAL
PE2007001544A 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS PE20081161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86648406P 2006-11-20 2006-11-20

Publications (1)

Publication Number Publication Date
PE20081161A1 true PE20081161A1 (es) 2008-08-15

Family

ID=39415431

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001544A PE20081161A1 (es) 2006-11-20 2007-11-08 COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS

Country Status (36)

Country Link
US (1) US7968587B2 (es)
EP (1) EP2094658B1 (es)
JP (1) JP5399259B2 (es)
KR (1) KR101121471B1 (es)
CN (1) CN101541749B (es)
AR (1) AR063559A1 (es)
AT (1) ATE538091T1 (es)
AU (1) AU2007324046B2 (es)
BR (1) BRPI0719092B8 (es)
CA (1) CA2670340C (es)
CL (1) CL2007003182A1 (es)
CO (1) CO6190513A2 (es)
CR (1) CR10802A (es)
CY (1) CY1112284T1 (es)
DK (1) DK2094658T3 (es)
EA (1) EA015627B1 (es)
EC (1) ECSP099350A (es)
ES (1) ES2376048T3 (es)
HR (1) HRP20120032T1 (es)
IL (1) IL198410A (es)
JO (1) JO2800B1 (es)
MA (1) MA31072B1 (es)
MX (1) MX2009005251A (es)
MY (1) MY154547A (es)
NO (1) NO342531B1 (es)
NZ (1) NZ576296A (es)
PE (1) PE20081161A1 (es)
PL (1) PL2094658T3 (es)
PT (1) PT2094658E (es)
RS (1) RS52191B (es)
SI (1) SI2094658T1 (es)
TN (1) TN2009000189A1 (es)
TW (1) TWI398438B (es)
UA (1) UA98777C2 (es)
WO (1) WO2008063867A2 (es)
ZA (1) ZA200903096B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
ES2488990T3 (es) 2008-02-22 2014-09-01 Radius Health, Inc. Moduladores selectivos del receptor de andrógenos
DK2297100T3 (da) * 2008-05-16 2012-12-17 Lilly Co Eli Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
AR078862A1 (es) 2009-11-13 2011-12-07 Lilly Co Eli Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
DK2568806T3 (en) 2010-05-12 2016-08-15 Radius Health Inc therapy Programs
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
EP2621901B1 (en) 2010-09-28 2015-07-29 Radius Health, Inc Selective androgen receptor modulators
US20140113824A1 (en) 2011-05-10 2014-04-24 Bayer Intellectual Property Gmbh Bicyclic (thio)carbonylamidines
CN103265479B (zh) * 2013-06-14 2017-12-08 南开大学 一种6‑氯甲基烟酸叔丁酯的合成方法
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3834824B1 (en) 2014-03-28 2025-10-22 Duke University Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
JOP20180072A1 (ar) * 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
KR20220035276A (ko) 2016-06-22 2022-03-21 일립시스 파마 리미티드 Ar+ 유방암 치료 방법
US20180185347A1 (en) 2016-11-16 2018-07-05 Transition Therapeutics (Ireland 2) Limited Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
AU2019297421B2 (en) 2018-07-04 2024-08-29 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD 1901-2HCL
CN113348163B (zh) 2019-02-12 2024-10-08 雷迪厄斯制药公司 方法和化合物
CA3166734A1 (en) * 2020-01-27 2021-08-05 Eirgen Pharma Ltd. Tetrahydrocyclopenta[b]indole compounds for the treatment of renal disease
US11986461B1 (en) * 2023-08-24 2024-05-21 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988820A (en) 1986-02-21 1991-01-29 Bayer Aktiengesellschaft Cycloalkano(1,2-B) indole-sulponamides
GB8924392D0 (en) 1989-10-30 1989-12-20 Bayer Ag Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides
GB9008108D0 (en) 1990-04-10 1990-06-06 Bayer Ag Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles
DE4027278A1 (de) 1990-08-29 1992-03-05 Bayer Ag Heterocyclisch substituierte indolsulfonamide
DE4131346A1 (de) 1991-09-20 1993-03-25 Bayer Ag Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
WO2001027086A1 (en) * 1999-10-14 2001-04-19 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
WO2003014082A1 (en) 2001-08-09 2003-02-20 Eli Lilly And Company Cyclopenta ` b ! indole derivatives as spla2 inhibitors
DE10164564B4 (de) 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
US7534897B2 (en) 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
US20060074124A1 (en) 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
US7019022B2 (en) 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CA2557745A1 (en) * 2004-03-03 2005-10-06 Eli Lilly And Company Bicyclic substituted indole-derivative steroid hormone nuclear receptor modulators
US20090170923A1 (en) * 2004-11-22 2009-07-02 Kristjan Gudmundsson Hcv inhibitors
WO2006065480A2 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
PA8663501A1 (es) 2005-02-17 2006-11-09 Wyeth Wyeth Derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilcondensados
BRPI0611705A2 (pt) 2005-06-24 2016-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
US20090022694A1 (en) 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
WO2008019825A1 (en) 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
DK2297100T3 (da) 2008-05-16 2012-12-17 Lilly Co Eli Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer

Also Published As

Publication number Publication date
TN2009000189A1 (en) 2010-10-18
JO2800B1 (en) 2014-03-15
PL2094658T3 (pl) 2012-05-31
CN101541749B (zh) 2013-03-27
ES2376048T3 (es) 2012-03-08
BRPI0719092B8 (pt) 2021-05-25
WO2008063867A2 (en) 2008-05-29
JP2010510231A (ja) 2010-04-02
EA015627B1 (ru) 2011-10-31
CY1112284T1 (el) 2015-12-09
AR063559A1 (es) 2009-02-04
IL198410A (en) 2013-09-30
KR20090082229A (ko) 2009-07-29
CR10802A (es) 2009-07-13
MY154547A (en) 2015-06-30
WO2008063867A3 (en) 2008-07-31
EP2094658A2 (en) 2009-09-02
NO20092103L (no) 2009-05-28
PT2094658E (pt) 2012-02-22
AU2007324046B2 (en) 2012-04-05
EA200970500A1 (ru) 2009-10-30
UA98777C2 (en) 2012-06-25
JP5399259B2 (ja) 2014-01-29
EP2094658B1 (en) 2011-12-21
HK1134089A1 (en) 2010-04-16
ECSP099350A (es) 2009-06-30
CN101541749A (zh) 2009-09-23
BRPI0719092A2 (pt) 2013-12-03
TWI398438B (zh) 2013-06-11
NZ576296A (en) 2011-11-25
MA31072B1 (fr) 2010-01-04
CO6190513A2 (es) 2010-08-19
TW200827347A (en) 2008-07-01
CL2007003182A1 (es) 2008-06-27
IL198410A0 (en) 2010-02-17
CA2670340A1 (en) 2008-05-29
AU2007324046A1 (en) 2008-05-29
KR101121471B1 (ko) 2012-02-28
ATE538091T1 (de) 2012-01-15
DK2094658T3 (da) 2012-02-13
ZA200903096B (en) 2010-07-28
SI2094658T1 (sl) 2012-04-30
HRP20120032T1 (hr) 2012-02-29
RS52191B (sr) 2012-10-31
BRPI0719092B1 (pt) 2020-08-18
US7968587B2 (en) 2011-06-28
MX2009005251A (es) 2009-08-19
US20100069404A1 (en) 2010-03-18
NO342531B1 (no) 2018-06-11
CA2670340C (en) 2014-05-20

Similar Documents

Publication Publication Date Title
PE20081161A1 (es) COMPUESTOS DE TETRAHIDROCICLOPENTA[b]INDOL COMO MODULADORES DEL RECEPTOR DE ANDROGENOS
PE20121010A1 (es) Derivados de bencimidazol
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20061084A1 (es) Compuestos derivados de 2-ciano-3-(halo)alcoxi-bencenosulfonamida
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20110152A1 (es) Nuevos derivados de sulfamida sustituida
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20050864A1 (es) Compuestos de heterociclilamino como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
PE20060334A1 (es) Derivados de piridina como antagonistas del receptor a2b de adenosina
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20091219A1 (es) Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
PE20080006A1 (es) Derivados de quinolina como agentes pesticidas
UY30874A1 (es) Derivados de n-(heteroaril)-1-heteroaril-1h-indol-2-carboxamidas, su preparacion y su aplicacion en terapéutica.
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20120691A1 (es) Derivados de n1-sulfonil-5-fluoropirimidinona
PE20121182A1 (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
PE20141678A1 (es) Indazol-3-carboxamidas y su uso como inhibidores de la ruta de senalizacion de wnt/b-catenina
PE20080947A1 (es) Derivados de n-(amino-heteroaril)-1h-indol-2-carboxamidas como antagonistas de receptores de tipo trpv1
PE20142282A1 (es) Nuevos derivados de aril-quinolina
PE20081831A1 (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b

Legal Events

Date Code Title Description
FG Grant, registration